缓释安非他酮治疗社交恐惧症。

Bupropion-SR in treatment of social phobia.

作者信息

Emmanuel N P, Brawman-Mintzer O, Morton W A, Book S W, Johnson M R, Lorberbaum J P, Ballenger J C, Lydiard R B

机构信息

Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston 29425, USA.

出版信息

Depress Anxiety. 2000;12(2):111-3. doi: 10.1002/1520-6394(2000)12:2<111::AID-DA9>3.0.CO;2-3.

DOI:10.1002/1520-6394(2000)12:2<111::AID-DA9>3.0.CO;2-3

PMID:11091936

Abstract

A 12-week, open label flexible dosing study was conducted to evaluate the efficacy of bupropion-SR in the treatment of generalized social phobia. The primary outcome measures include the Clinical Global Impression of Improvement (CGI-I) and the Brief Social Phobia Rating Scale (BSPS). A total of 18 subjects were enrolled. Five of the ten subjects who completed all 12 weeks were considered as responders. Response to treatment was defined as a CGI-I score of 1 or 2, ("much improved" or "very much improved," respectively) and a > 50% decrease in BSPS score. The final doses for the completers ranged between 200 and 400 mg/day (mean 366 +/- 68 mg/day). The medication was generally well tolerated. Findings from this open-label trial suggest that bupropion-SR may be useful in treating generalized social phobia.

摘要

开展了一项为期12周的开放标签灵活剂量研究，以评估安非他酮缓释剂治疗广泛性社交恐惧症的疗效。主要结局指标包括临床总体印象改善量表（CGI-I）和社交恐惧症简要评定量表（BSPS）。共招募了18名受试者。完成全部12周治疗的10名受试者中有5名被视为有反应者。治疗反应定义为CGI-I评分为1或2（分别为“明显改善”或“非常显著改善”）且BSPS评分降低>50%。完成治疗者的最终剂量范围为200至400毫克/天（平均366±68毫克/天）。该药物总体耐受性良好。这项开放标签试验的结果表明，安非他酮缓释剂可能对治疗广泛性社交恐惧症有用。